RDIF proposes Pfizer conduct joint trials with Sputnik Light as booster shot

Published On 2021-08-12 06:30 GMT | Update On 2021-08-12 11:52 GMT

New Delhi: The Russian Direct Investment Fund (RDIF) has proposed that US drugmaker Pfizer start joint trials with Sputnik Light as a booster COVID-19 vaccine shot, the RDIF said on Wednesday.

"Delta cases surge in US & Israel shows mRNA vaccines need a heterogeneous booster to strengthen & prolong immune response. #SputnikV pioneered mix&match approach, combo trials & showed 83.1% efficacy vs Delta. Today RDIF offers Pfizer to start trial with Sputnik Light as booster," it said in a Tweet.

It further said that Sputnik V is the first in the world to offer combo trial to AstraZeneca in November 2020, co-sponsored mix&match trials with AstraZeneca, Moderna and Sinopharm.

"Sputnik V was the 1st in the world to offer combo trial to AstraZeneca in Nov 2020, co-sponsored mix&match trials with AstraZeneca, Moderna & Sinopharm. Since then heterogeneous boosting pioneered by Sputnik proved to be effective vs mutations," it added further.

According to an official statement, the data collected by the health ministry confirms that Sputnik V remains protective against newly detected variants and retains one of the best safety and efficacy parameters.

The Russian Ministry of Health has also published data on Sputnik V's efficacy against the Delta variant. The vaccine is 83.1 per cent effective and shows 6x reduction of infection risk. Sputnik V is also 94.4 per cent effective against hospitalizations with 18x reduction in hospitalisation risk," the RDIF statement said.

Furthermore, real-world data obtained during mass vaccinations in Argentina, Bahrain, Hungary, Mexico, Russia, Serbia, the Philippines and UAE demonstrate lack of serious adverse events (such as CVTs or myocarditis). In several countries where multiple vaccines are used, the Russian vaccine has demonstrate done of the best safety and efficacy parameters.

At present, Sputnik V has been approved in 69 countries with total population exceeding 3.7 billion people - nearly half of the global population.

RDIF has concluded production partnerships with more than 20 companies in 14 countries, including the leading manufacturers in India, China, South Korea, Argentina, Mexico and other countries.

The RDIF statement also said that the two-dose Sputnik V vaccine, the single dose Sputnik Light vaccine is also demonstrating high safety and efficacy results in Argentina. Sputnik Light is the first component of Sputnik V (recombinant human adenovirus serotype number 26 (rAd26)).

In particular, data from the Ministry of Health of the province of Buenos Aires showed that Sputnik Light had helped to elicit antibodies in 94 per cent of those vaccinated and provided for a strong immune response.

Article Source : ANI

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

RDIF proposes Pfizer conduct joint trials with Sputnik Light as booster shot

Similar News

Gilead Sciences gets European Commission marketing authorization for twice yearly Yeytuo for HIV prevention

Eris Lifesciences receives ANVISA approval for Ahmedabad Sterile Injectable facility

Bayer Gadoquatrane new drug application accepted for review by USFDA

Samir Desai, President-BU Biologics at Zydus Lifesciences, passes away

USFDA approves Gland Pharma Vasopressin in 5% Dextrose RTU Injection

Unichem Labs gets EIR from USFDA for Roha API facility

Biocon Pharma bags tentative USFDA nod for diabetes medicine Sitagliptin

Eris Lifesciences Slapped Rs 17 Crore GST Notice Over Novartis Zomelis Deal